Anticardiolipin and Anti-(32 Glycoprotein I Antibodies in Pregnant Women with Severe Pre-Eclampsia

Abstract
Background: APA have been associated with a number of obstetric complications however their role in the pathogen-esis of preeclampsia has remained an issue of controversy.
Aim of the Study: 1- Detection of Anticardiolipin antibodies and Anti-(32 glycoprotein I antibodies in pregnant women with severe pre-eclampsia. 2- Estimation of the prevalence of APA in pregnant women with severe pre-eclampsia.
Patients and Methods: This is a case control study. Eighty pregnant women diagnosed of severe pre-eclampsia and twenty age-parity matched normal on-going pregnant women were recruited as participants for the study. Antiphospholipid antibodies were assayed using Dilute Russel Viper's Venom (DRVV) Lupus Anticoagulant (LA screen and confirm kits), Anticardiolipin Antibody (ACA) Enzyme Linked Immuno-sorbent Assay (ELISA) kits and Anti-(32 glycoprotein I anti-bodies ELISA-based test system were used.
Results: The prevalence of APLA in severe pre-eclampsia was 6.25%, while none (0%) of the controls was positive.
Conclusion: This study using DRVVT lupus anticoagulant, Anticardiolipin and Anti-(32 glycoprotein I assays has found the prevalence of APA in severe pre-eclampsia women seen at Women’s Health Hospital, Assiut University to be 6.25%, while none (0%) of the controls was positive. These findings suggested that there is a relation between presence of APA and development of severe pre-eclampsia.